SCHEMBL1008596

SCHEMBL1008596

CC(C)(C)[Si](C)(C)OCCCCCCCCC=O

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
DUT P33316 2/20 0.38
FAAH O00519 2/20 0.36
TRPV1 Q8NER1 1/20 0.36
HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31240526 1.00 TSHR (0.40) TSHRDUTFAAHTRPV1HIF1A
SCHEMBL2917304 1.00 TSHR (0.40) TSHRDUTFAAHTRPV1HIF1A
SCHEMBL27241090 1.00 TSHR (0.40) TSHRDUTFAAHTRPV1HIF1A
SCHEMBL201004 0.98 DUT (0.39) TSHRDUTFAAHTRPV1HIF1A
SCHEMBL852468 0.92 DUT (0.40) TSHRDUTFAAHTRPV1HIF1A
SCHEMBL573170 0.84 DUT (0.35) DUT
SCHEMBL27241092 0.83 DUT (0.42) DUT
SCHEMBL14245094 0.83 DUT (0.42) DUT
SCHEMBL9007756 0.83 DUT (0.42) DUT
SCHEMBL2245848 0.82 TSHR (0.41) TSHRDUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739652-A1 LIPIDS AND COMPOSITIONS THEREOF Kernal Biologics, Inc. (US) 2026-05-13 EP disclosed
US-20260116845-A1 LIPIDS AND COMPOSITIONS THEREOF KERNAL BIOLOGICS INC (US) 2026-04-30 US disclosed
WO-2025010290-A1 LIPIDS AND COMPOSITIONS THEREOF KERNAL BIOLOGICS, INC. (US) 2025-01-09 WO disclosed
CN-107151201-B Terminally conjugated trienal aldehyde-condensed aldehyde compound and method for producing terminally conjugated triene aldehyde compound using same 信越化学工业株式会社 2021-05-25 CN disclosed
US-9822050-B2 Terminal conjugated trienal acetal compound and method for producing terminal conjugated trienal compound using the same SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-11-21 US disclosed
US-20170253548-A1 Terminal Conjugated Trienal Acetal Compound and Method for Producing Terminal Conjugated Trienal Compound Using the Same SHIN-ETSU CHEMICAL CO., LTD. (JP) 2017-09-07 US disclosed
EP-3214063-A1 TERMINAL CONJUGATED TRIENAL ACETAL COMPOUND AND METHOD FOR PRODUCING TERMINAL CONJUGATED TRIENAL COMPOUND USING THE SAME Shin-Etsu Chemical Co., Ltd. (JP) 2017-09-06 EP disclosed
US-9226503-B2 Composition and method for attraction of emerald ash borer Agrilus planipennis fairmaire (coleoptera: buprestidae) HER MAJESTY THE QUEEN, IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATURAL RESOURCES CANADA (CA) 2016-01-05 US disclosed
US-20150132252-A1 Composition and Method for Attraction of Emerald Ash Borer Agrilus Planipennis Fairmaire (Coleoptera: Buprestidae) HER MAJESTY THE QUEEN IN RIGHT OF CANADA, AS REPRESENTED BY THE MINISTER OF NATURAL RESOURCES (CA) 2015-05-14 US disclosed
US-20130028858-A1 COMPOSITION AND METHOD FOR ATTRACTION OF EMERALD ASH BORER AGRILUS PLANIPENNIS FAIRMAIRE (COLEOPTERA: BUPRESTIDAE) NATIONAL RESEARCH COUNCIL OF CANADA (CA) 2013-01-31 US disclosed
US-20110028746-A1 METHOD FOR THE DECARBOXYLATIVE HYDROFORMYLATION OF ALPHA, BETA- UNSATURATED CARBOXYLIC ACIDS BASF SE (DE) 2011-02-03 US disclosed
EP-2268397-A1 METHOD FOR THE DECARBOXYLATIVE HYDROFORMYLATION OF , ALPHA, BETA -UNSATURATED CARBOXYLIC ACIDS BASF SE (DE) 2011-01-05 EP disclosed
WO-2009118341-A1 METHOD FOR THE DECARBOXYLATIVE HYDROFORMYLATION OF α,β-UNSATURATED CARBOXYLIC ACIDS BASF SE (DE) 2009-10-01 WO disclosed
US-7335680-B2 Pyrrolidine derivatives as prostaglandin modulators LABORATOIRES SERONO SA (CH) 2008-02-26 US disclosed
US-20050176800-A1 Pyrrolidine derivatives as prostaglandin modulators APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028746-A1 METHOD FOR THE DECARBOXYLATIVE HYDROFORMYLATION OF ALPHA, BETA- UNSATURATED CARBOXYLIC ACIDS PCCA, CBR3, CBR1 TSHR 2153/4885DUT 1843/4885FAAH 1734/4885
US-20050176800-A1 Pyrrolidine derivatives as prostaglandin modulators PGF, PTGIS, PTGIR TSHR 3698/4885DUT 892/4885FAAH 422/4885
US-20170253548-A1 Terminal Conjugated Trienal Acetal Compound and Method for Producing Terminal Conjugated Trienal Compound Using the Same GGT1, APEH, PSMA5 TSHR 1880/4885DUT 278/4885FAAH 1102/4885
US-20260116845-A1 LIPIDS AND COMPOSITIONS THEREOF LIPC, LIPA, NPC1L1 TSHR 1603/4885DUT 1358/4885FAAH 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.